Healthcare Industry News: Neuropathic Pain
News Release - February 20, 2008
Depomed Names Abid Rawn Vice President of Sales and MarketingMENLO PARK, Calif.--(HSMN NewsFeed)--Depomed, Inc. (NASDAQ:DEPO ) today announced that Abid Rawn has joined the company as vice president of Sales and Marketing. In this role, Mr. Rawn will be involved in all aspects of the company’s commercial operations, from strategic product selection through commercialization.
Mr. Rawn has more than 25 years of commercial experience in the pharmaceutical industry. He spent 18 years at GlaxoSmithKline in a variety of marketing and commercial operations positions, including as general manager of Glaxo Wellcome Saudi Arabia, director of Strategic Planning and Lifecycle Management, group director of New Products Planning, and director of Marketing Planning and Development. Mr. Rawn most recently served as director of BioOncology Business Unit operations for Genentech, and also served in various sales and marketing positions at Bristol Myers and Eli Lilly early in his career. Mr. Rawn received B.S. degrees in Pharmacy and Zoology from the University of Wyoming.
“I have known Abid for 15 years and worked closely with him during our careers at GSK, both internationally and domestically. He has the skills, broad experience and drive to make a very significant contribution to the success of our commercial activities here at Depomed,” stated Carl A. Pelzel, president and chief executive officer of Depomed.
Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuFormTM drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in Canada by Biovail Corporation. ProQuin® XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology and Ob/Gyn specialties by Watson Pharmaceuticals. Product candidate Gabapentin GR is currently in clinical development for the treatment of Neuropathic Pain and menopausal hot flashes. Additional information about Depomed may be found on its website, www.depomed.com.
Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. The inclusion of forward-looking statements, including those related to the capabilities of our management team, expectations regarding product development, and potential benefits of our products and product candidates, should not be regarded as a representation that any of our plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation, risks and uncertainties related to: our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; our ability to successfully commercialize our products; the success of our collaborative arrangements with development and commercialization partners; and other risks detailed in our filings with the Securities and Exchange Commission filings, including our most recent Annual Report on Form 10-K and our most recent Quarterly Report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to revise or update this release to reflect events or circumstances that occur after the date of this release.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.